Availability: TB-500 is not currently orderable from Rebody. Vial size, chemical form, and schedule examples are future label checks, not current options.
The short answer
The best TB-500 option is the one whose label verifies the exact seven-amino-acid form, concentration, usable supply, and cost per prescribed day.
Options at a glance
| Option | What changes | What must be verified | Boundary |
|---|---|---|---|
| 5 mg TB-500 vial | Total active and refill burden | Exact identity, concentration, supply | Best when it covers the course without waste |
| 10 mg TB-500 vial | Total active and up-front price | Beyond-use date and cost per day | Best when the full quantity is usable |
| Weekly routine | Handling frequency | Final prescription schedule | Best when the label uses that cadence |
What belongs in this category
A TB-500 page must start with identity. The vial should name the exact seven-amino-acid substance rather than using “thymosin” as shorthand. Once identity is verified, compare concentration, prescribed amount, frequency, total supply, storage, and refill timing.
Five and ten milligrams describe total quantity. They do not decide the amount per injection or prove that a larger vial works better. A weekly routine is real only when the final prescription actually uses that cadence.
What these molecules are
TB-500 commonly refers to an acetylated seven-amino-acid sequence related to residues 17–23 of thymosin beta-4. Full thymosin beta-4 is a 43-amino-acid protein. The non-acetylated LKKTETQ fragment used in some laboratory work is also not automatically identical to an acetylated finished vial.
That is why a TB-500 label needs more than a brand-like name. Exact sequence or substance, concentration, fill volume, total active, and prescription directions must agree.
What the research measured
FDA's review identified no human TB-500 exposure, pharmacokinetic, safety, or efficacy study by any route. In the direct laboratory record, a fibroblast scratch assay using 50 micrograms per milliliter for eight hours found no significant wound-closure difference from vehicle.
Frequently cited wound work tested full thymosin beta-4 or a non-acetylated fragment in laboratory or animal models. Those results belong to the exact molecule tested. Package size and weekly convenience change the routine, not molecular identity.
Which option wins this comparison
Choose a TB-500 vial only after exact identity is verified. Among verified options, the practical winner covers the prescribed course at the lower cost per day without exceeding the beyond-use date or creating avoidable refill gaps.
The 10 mg vial wins on supply only when the extra quantity is usable. The 5 mg vial wins when it better matches a shorter course or avoids waste. A weekly option wins only if the current label—not an internet protocol—prescribes weekly use.
Strength, concentration, and dose are different facts
Keep total active, concentration, injection volume, amount per dose, and frequency separate. Syringe units are volume markings and cannot be copied between concentrations. Ask the dispensing pharmacy to reconcile the label if the math is unclear.
Do not infer a schedule from thymosin beta-4 studies, a competitor's vial, or a forum stack. Do not double after a missed dose or combine TB-500 with another active in one syringe unless the prescription explicitly directs it.
What the routine changes in real life
The practical TB-500 routine includes injection days, clean preparation, site rotation, sharps disposal, storage, travel, and refill lead time. Count those handling events across the full course.
A lower-frequency schedule may reduce handling burden, but it does not create stronger evidence. If work or travel repeatedly breaks the prescribed cadence, ask the care team to solve the schedule instead of clustering doses.
Storage, shipping, and travel
Use the finished TB-500 vial's exact storage and after-opening instructions. Do not borrow a temperature range from BPC-157, KPV, or full thymosin beta-4. Keep the lot and beyond-use date with the original label.
After excess heat, freezing, a broken seal, crack, leak, cloudiness, particles, or color change, hold the dose and contact the dispensing pharmacy. During travel, prevent direct vial-to-ice contact and plan for clean syringe and sharps handling.
Side effects and urgent symptoms
No identified human TB-500 study establishes systemic safety. Immediate injection risks include pain, bruising, bleeding, irritation, contamination, and infection. Spreading warmth or redness, drainage, red streaking, fever, facial swelling, breathing difficulty, or fainting needs prompt help.
Tested athletes must also account for anti-doping rules. Pregnancy, breastfeeding, cancer or immune treatment, clotting concerns, and medication interactions require direct prescriber review.
Price, supply, and refills
Calculate price per prescribed day from verified supply, not the vial's milligram headline. Include syringes, swabs, shipping, storage equipment if needed, and the number of refills required for the course.
A larger vial is better value only when the concentration, schedule, and beyond-use date allow the full amount to be used. Otherwise the lower per-milligram price can hide waste.
Questions people ask before starting
Can I take BPC-157 and TB-500 every day?
Use the exact schedule printed on the prescription label. TB-500 and BPC-157 have different identities and historical schedules, so the current vial label—not a historical protocol or online stack—sets the actual cadence.
What are the risks of taking TB-500?
FDA's review identified no human TB-500 exposure, pharmacokinetic, safety, or efficacy study. Injection risks include pain, bruising, contamination, and infection, and TB-500 is prohibited for tested athletes. Package size and weekly convenience do not change that safety record.
Is TB-500 the same as thymosin beta-4?
No. TB-500 commonly refers to a seven-amino-acid fragment related to residues 17–23 of thymosin beta-4. Thymosin beta-4 is a 43-amino-acid protein, so its human wound studies cannot be presented as TB-500 trials. Exact identity must be verified before comparing concentration, supply, or price.
What changes between 5 mg and 10 mg vials?
Five and ten milligrams usually describe total active in the vial, not the amount used at one time. Concentration, prescribed dose, frequency, days of supply, price per day, and refill timing decide which package is more practical. The winner covers the prescribed course without waste.
What did the strongest study measure?
The most relevant fragment evidence comes from aged-mouse wounds and laboratory migration or sprouting assays; full thymosin beta-4 and TB-500 must remain separate.
How do route and product form change the answer?
The direct TB-500 record is preclinical; human studies of full thymosin beta-4 belong to the 43-amino-acid parent protein.
What should happen after a missed dose?
Do not double the next dose during a TB-500 vial and routine. Note when it was missed and ask the care team or dispensing pharmacy whether to resume or shift the schedule; a missed dose is not a reason to improvise.
How should the product be stored for travel?
For this TB-500 vial and routine, travel with the product in its original labeled container and follow its exact temperature range. Protect it from freezing and direct contact with ice. After a warm shipment, leak, crack, broken seal, cloudiness, particles, or color change, hold the dose for guidance from the dispensing pharmacy; the finished formula controls the answer.
Is a 10 mg TB-500 vial a higher dose than a 5 mg vial?
Not by itself. Ten milligrams states the total quantity in the vial. The prescribed dose depends on concentration, injection volume, active amount per use, and frequency. A larger vial may provide more doses at the same amount, or it may use a different fill volume. Never change syringe volume because the vial contains more total active.
Is TB-500 supposed to be injected weekly?
Only if the final prescription says so. Historical protocols and seller charts do not determine the current finished product's schedule. A weekly cadence can reduce handling burden, but it does not prove stronger results or apply across concentrations. Confirm what happens after a missed dose before travel or the first injection day.
How can a label prove the vial is actually TB-500?
The label and product documentation should identify the exact substance, not merely say “thymosin.” TB-500 commonly refers to an acetylated seven-amino-acid fragment related to thymosin beta-4, while the parent protein contains 43 amino acids. Concentration, fill volume, total active, and prescription directions should all be internally consistent.
What should happen to TB-500 during travel?
Carry it in the original labeled container, follow the exact temperature range, prevent direct contact with ice, and keep clean syringes separate from used sharps. Check airline and destination requirements. After excess heat, accidental freezing, a leak, crack, broken seal, cloudiness, particles, or color change, hold the dose for pharmacy guidance.
Verify identity before discussing any injection routine
"Thymosin" on its own is too vague. Full thymosin beta-4 has 43 amino acids; TB-500 commonly refers to a shorter acetylated fragment related to the LKKTETQ region; some laboratory papers test an unacetylated fragment. A finished vial should identify the actual substance. Once identity is clear, concentration, volume, total active, schedule, storage, and supply become meaningful. Human topical thymosin beta-4 findings remain attached to the parent protein, while TB-500 retains its narrower fragment record.
Bottom line
The best TB-500 option is the one whose label verifies the exact seven-amino-acid form, concentration, usable supply, and cost per prescribed day.
Keep reading
- At-Home Peptide Injections for Recovery
- TB-500 Injection Supplies, Storage, and Travel
- Weekly Recovery Peptide Injections
Primary sources
- https://pubmed.ncbi.nlm.nih.gov/12581423/
- https://pubmed.ncbi.nlm.nih.gov/14500546/
- https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- https://www.wada-ama.org/en/resources/world-anti-doping-program/prohibited-list